CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with ...

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS ...

Newer therapies for acute lymphoblastic leukemia target cancer cells more precisely, reducing side effects compared to ...

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.

A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients ...

Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma ...

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more ...

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

Panelists discuss key advice for patients and caregivers navigating advanced prostate cancer, highlighting essential insights ...

Panelists discuss the key takeaways from their experiences in treating advanced prostate cancer, emphasizing valuable lessons ...

Circulating tumor cell (CTC) count can help inform treatment decisions for patients with cancer, including which patients are ...